D
DiaMedica Therapeutics Inc.
DMAC
$5.80
$0.193.39%
D
Sell
5/7/2024Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index and total return index.
E
Sell
3/27/2024Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 3/27/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1178 to -$0.1358, EBIT declined 13.4% from -$5.16M to -$5.85M, and the quick ratio declined from 21.56 to 19.12.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 3/27/2024 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1178 to -$0.1358, EBIT declined 13.4% from -$5.16M to -$5.85M, and the quick ratio declined from 21.56 to 19.12.
D
Sell
3/6/2024Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 3/6/2024 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 3/6/2024 due to an increase in the volatility index and total return index.
E
Sell
2/20/2024Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 2/20/2024 due to a decline in the volatility index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 2/20/2024 due to a decline in the volatility index.
D
Sell
2/2/2024Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index and total return index.
E
Sell
1/12/2024Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 1/12/2024 due to a decline in the total return index and volatility index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 1/12/2024 due to a decline in the total return index and volatility index.
D
Sell
12/27/2023Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 12/27/2023 due to an increase in the total return index and volatility index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 12/27/2023 due to an increase in the total return index and volatility index.
E
Sell
12/6/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 12/6/2023 due to a decline in the volatility index, total return index and valuation index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 12/6/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
11/20/2023Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and valuation index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and valuation index.
E
Sell
11/15/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and growth index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and growth index.
D
Sell
5/12/2023Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 5/12/2023 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 5/12/2023 due to an increase in the volatility index and total return index.
E
Sell
4/27/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 4/27/2023 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 23.45 to 15.49, EBIT declined 27.01% from -$3.13M to -$3.97M, and earnings per share declined from -$0.1157 to -$0.1419.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 4/27/2023 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 23.45 to 15.49, EBIT declined 27.01% from -$3.13M to -$3.97M, and earnings per share declined from -$0.1157 to -$0.1419.
D
Sell
3/30/2023Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 3/30/2023 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D- from E+ on 3/30/2023 due to an increase in the volatility index and total return index.
E
Sell
3/15/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 3/15/2023 due to a decline in the volatility index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D- on 3/15/2023 due to a decline in the volatility index.
D
Sell
3/14/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 25.09 to 23.45.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 25.09 to 23.45.
D
Sell
7/29/2022Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 7/29/2022 due to an increase in the volatility index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 7/29/2022 due to an increase in the volatility index.
D
Sell
7/13/2022Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 7/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/6/2022Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 05/06/2022.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 05/06/2022.
D
Sell
4/20/2022Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell
11/9/2021Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, growth index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, growth index and total return index.
D
Sell
5/14/2020Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 5/14/2020 due to a large increase in the growth index, solvency index and valuation index. The quick ratio increased from 6.6 to 14.58, debt to equity declined from 0.01 to 0, and EBIT increased 13.21% from -$2.77M to -$2.4M.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 5/14/2020 due to a large increase in the growth index, solvency index and valuation index. The quick ratio increased from 6.6 to 14.58, debt to equity declined from 0.01 to 0, and EBIT increased 13.21% from -$2.77M to -$2.4M.
D
Sell
5/12/2020Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 5/12/2020 due to a decline in the efficiency index, total return index and valuation index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 5/12/2020 due to a decline in the efficiency index, total return index and valuation index.
D
Sell
4/13/2020Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 4/13/2020 due to an increase in the volatility index, valuation index and growth index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 4/13/2020 due to an increase in the volatility index, valuation index and growth index.
D
Sell
3/24/2020Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 3/24/2020 due to a decline in the volatility index, solvency index and growth index. Operating cash flow declined 51.38% from -$1.23M to -$1.87M, the quick ratio declined from 8.64 to 6.6, and EBIT declined 4.1% from -$2.66M to -$2.77M.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 3/24/2020 due to a decline in the volatility index, solvency index and growth index. Operating cash flow declined 51.38% from -$1.23M to -$1.87M, the quick ratio declined from 8.64 to 6.6, and EBIT declined 4.1% from -$2.66M to -$2.77M.
D
Sell
1/14/2020Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 1/14/2020 due to an increase in the total return index and volatility index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 1/14/2020 due to an increase in the total return index and volatility index.
D
Sell
10/31/2019Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 10/31/2019 due to a decline in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 10/31/2019 due to a decline in the volatility index and total return index.
D
Sell
8/19/2019Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 8/19/2019 due to a noticeable increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.272 to -$0.2061, net income increased 24.08% from -$3.25M to -$2.47M, and EBIT increased 19.88% from -$3.42M to -$2.74M.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 8/19/2019 due to a noticeable increase in the efficiency index, growth index and valuation index. Earnings per share increased from -$0.272 to -$0.2061, net income increased 24.08% from -$3.25M to -$2.47M, and EBIT increased 19.88% from -$3.42M to -$2.74M.
D
Sell
7/1/2019Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 7/1/2019 due to a decline in the valuation index and total return index.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 7/1/2019 due to a decline in the valuation index and total return index.
D
Sell
6/5/2019Upgraded
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 6/5/2019 due to an increase in the volatility index and valuation index.
DiaMedica Therapeutics Inc. (DMAC) was upgraded to D from D- on 6/5/2019 due to an increase in the volatility index and valuation index.
D
Sell
5/21/2019Downgrade
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 5/21/2019 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.1213 to -$0.272, operating cash flow declined 64.01% from -$1.91M to -$3.13M, and EBIT declined 34.63% from -$2.54M to -$3.42M.
DiaMedica Therapeutics Inc. (DMAC) was downgraded to D- from D on 5/21/2019 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.1213 to -$0.272, operating cash flow declined 64.01% from -$1.91M to -$3.13M, and EBIT declined 34.63% from -$2.54M to -$3.42M.
D
Sell
6/5/2018Downgrade
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 6/5/2018 due to a noticeable decline in the efficiency index and total return index.
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 6/5/2018 due to a noticeable decline in the efficiency index and total return index.
D
Sell
5/16/2018Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 5/16/2018 due to an increase in the growth index and total return index.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 5/16/2018 due to an increase in the growth index and total return index.
D
Sell
5/1/2018Downgrade
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from C- on 5/1/2018 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from -$0.0074 to -$0.0135, operating cash flow declined 52.56% from -$679 to -$1.04M, and EBIT declined 47.09% from -$720.3 to -$1.06M.
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from C- on 5/1/2018 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from -$0.0074 to -$0.0135, operating cash flow declined 52.56% from -$679 to -$1.04M, and EBIT declined 47.09% from -$720.3 to -$1.06M.
C
Hold
4/11/2018Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to C- from D on 4/11/2018 due to a substantial increase in the total return index and volatility index.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to C- from D on 4/11/2018 due to a substantial increase in the total return index and volatility index.
D
Sell
1/31/2018Downgrade
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 1/31/2018 due to a decline in the total return index.
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 1/31/2018 due to a decline in the total return index.
D
Sell
1/16/2018Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 1/16/2018 due to an increase in the total return index and volatility index.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 1/16/2018 due to an increase in the total return index and volatility index.
D
Sell
12/14/2017Downgrade
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 12/14/2017 due to a noticeable decline in the total return index.
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to D from D+ on 12/14/2017 due to a noticeable decline in the total return index.
D
Sell
11/28/2017Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 11/28/2017 due to a large increase in the efficiency index, valuation index and total return index. Net income increased 16.36% from -$1.07M to -$896.1.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D+ from D on 11/28/2017 due to a large increase in the efficiency index, valuation index and total return index. Net income increased 16.36% from -$1.07M to -$896.1.
D
Sell
4/28/2017Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D from D- on 4/28/2017 due to a noticeable increase in the solvency index, total return index and growth index. Debt to equity declined from 0.3 to 0, earnings per share increased from -$0.0099 to -$0.0026, and the quick ratio increased from 2.02 to 2.77.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D from D- on 4/28/2017 due to a noticeable increase in the solvency index, total return index and growth index. Debt to equity declined from 0.3 to 0, earnings per share increased from -$0.0099 to -$0.0026, and the quick ratio increased from 2.02 to 2.77.
D
Sell
4/3/2017Upgraded
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D- from E+ on 4/3/2017 due to an increase in the volatility index and total return index.
DiaMedica Therapeutics Inc. (DMCAF) was upgraded to D- from E+ on 4/3/2017 due to an increase in the volatility index and total return index.
E
Sell
12/28/2016Downgrade
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to E+ from D- on 12/28/2016 due to a decline in the volatility index.
DiaMedica Therapeutics Inc. (DMCAF) was downgraded to E+ from D- on 12/28/2016 due to a decline in the volatility index.
D
Sell
12/9/2016Downgrade
Diamedica Inc. (DMCAF) was downgraded to D- from D on 12/9/2016 due to a noticeable decline in the efficiency index, growth index and total return index. Operating cash flow declined 135.33% from -$401.4 to -$944.6, net income declined 78.87% from -$530.6 to -$949.1, and EBIT declined 74.99% from -$554.5 to -$970.3.
Diamedica Inc. (DMCAF) was downgraded to D- from D on 12/9/2016 due to a noticeable decline in the efficiency index, growth index and total return index. Operating cash flow declined 135.33% from -$401.4 to -$944.6, net income declined 78.87% from -$530.6 to -$949.1, and EBIT declined 74.99% from -$554.5 to -$970.3.
D
Sell
10/17/2016Downgrade
Diamedica Inc. (DMCAF) was downgraded to D from D+ on 10/17/2016 due to a decline in the total return index and volatility index.
Diamedica Inc. (DMCAF) was downgraded to D from D+ on 10/17/2016 due to a decline in the total return index and volatility index.
D
Sell
9/16/2016Upgraded
Diamedica Inc. (DMCAF) was upgraded to D+ from D on 9/16/2016 due to an increase in the valuation index and total return index.
Diamedica Inc. (DMCAF) was upgraded to D+ from D on 9/16/2016 due to an increase in the valuation index and total return index.
D
Sell
9/1/2016Downgrade
Diamedica Inc. (DMCAF) was downgraded to D from C- on 9/1/2016 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from -0.38 to 0, total capital declined 71.98% from -$602.7 to -$1.04M, and net income declined 59.48% from -$332.7 to -$530.6.
Diamedica Inc. (DMCAF) was downgraded to D from C- on 9/1/2016 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from -0.38 to 0, total capital declined 71.98% from -$602.7 to -$1.04M, and net income declined 59.48% from -$332.7 to -$530.6.
C
Hold
5/31/2016Upgraded
Diamedica Inc. (DMCAF) was upgraded to C- from D on 5/31/2016 due to a significant increase in the efficiency index, growth index and total return index. Net income increased 37.25% from -$530.2 to -$332.7, earnings per share increased from -$0.0058 to -$0.0039, and EBIT increased 28.97% from -$495.4 to -$351.9.
Diamedica Inc. (DMCAF) was upgraded to C- from D on 5/31/2016 due to a significant increase in the efficiency index, growth index and total return index. Net income increased 37.25% from -$530.2 to -$332.7, earnings per share increased from -$0.0058 to -$0.0039, and EBIT increased 28.97% from -$495.4 to -$351.9.
D
Sell
4/29/2016Downgrade
Diamedica Inc. (DMCAF) was downgraded to D from D+ on 4/29/2016 due to a decline in the growth index, total return index and valuation index. EBIT declined 170.71% from -$183 to -$495.4, operating cash flow declined 128.35% from -$172.5 to -$393.9, and earnings per share declined from -$0.0035 to -$0.0078.
Diamedica Inc. (DMCAF) was downgraded to D from D+ on 4/29/2016 due to a decline in the growth index, total return index and valuation index. EBIT declined 170.71% from -$183 to -$495.4, operating cash flow declined 128.35% from -$172.5 to -$393.9, and earnings per share declined from -$0.0035 to -$0.0078.
D
Sell
3/28/2016Upgraded
Diamedica Inc. (DMCAF) was upgraded to D+ from D on 3/28/2016 due to an increase in the volatility index and total return index.
Diamedica Inc. (DMCAF) was upgraded to D+ from D on 3/28/2016 due to an increase in the volatility index and total return index.
D
Sell
3/11/2016Downgrade
Diamedica Inc. (DMCAF) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
Diamedica Inc. (DMCAF) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
C
Hold
2/23/2016Upgraded
Diamedica Inc. (DMCAF) was upgraded to C- from D+ on 2/23/2016 due to a large increase in the total return index and volatility index.
Diamedica Inc. (DMCAF) was upgraded to C- from D+ on 2/23/2016 due to a large increase in the total return index and volatility index.
D
Sell
12/2/2015Downgrade
Diamedica Inc. (DMCAF) was downgraded to D+ from C on 12/2/2015 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 28.84% from -$338.8 to -$241.1.
Diamedica Inc. (DMCAF) was downgraded to D+ from C on 12/2/2015 due to a significant decline in the efficiency index, total return index and valuation index. Net income declined 28.84% from -$338.8 to -$241.1.
C
Hold
9/2/2015Upgraded
Diamedica Inc. (DMCAF) was upgraded to C from D+ on 9/2/2015 due to an increase in the total return index, growth index and volatility index. Operating cash flow increased 67.62% from -$346.5 to -$580.8.
Diamedica Inc. (DMCAF) was upgraded to C from D+ on 9/2/2015 due to an increase in the total return index, growth index and volatility index. Operating cash flow increased 67.62% from -$346.5 to -$580.8.
D
Sell
6/1/2015Downgrade
Diamedica Inc. (DMCAF) was downgraded to D+ from C- on 6/1/2015 due to a decline in the growth index.
Diamedica Inc. (DMCAF) was downgraded to D+ from C- on 6/1/2015 due to a decline in the growth index.
C
Hold
5/1/2015Downgrade
Diamedica Inc. (DMCAF) was downgraded to C- from C on 5/1/2015 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.4 to 0.12.
Diamedica Inc. (DMCAF) was downgraded to C- from C on 5/1/2015 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.4 to 0.12.
C
Hold
12/2/2014Upgraded
Diamedica Inc. (DMCAF) was upgraded to C from D on 12/2/2014 due to a significant increase in the efficiency index, valuation index and growth index.
Diamedica Inc. (DMCAF) was upgraded to C from D on 12/2/2014 due to a significant increase in the efficiency index, valuation index and growth index.
D
Sell
9/4/2014Downgrade
Diamedica Inc. (DMCAF) was downgraded to D from C- on 9/4/2014 due to a significant decline in the efficiency index, valuation index and solvency index. Total capital declined 121.6% from -$398.7 to $86.1, and net income declined 41.13% from -$2.04M to -$1.2M.
Diamedica Inc. (DMCAF) was downgraded to D from C- on 9/4/2014 due to a significant decline in the efficiency index, valuation index and solvency index. Total capital declined 121.6% from -$398.7 to $86.1, and net income declined 41.13% from -$2.04M to -$1.2M.
C
Hold
6/5/2014Upgraded
Diamedica Inc. (DMCAF) was upgraded to C- from D- on 6/5/2014 due to a significant increase in the efficiency index and valuation index. Net income increased 44.08% from -$1.41M to -$2.04M.
Diamedica Inc. (DMCAF) was upgraded to C- from D- on 6/5/2014 due to a significant increase in the efficiency index and valuation index. Net income increased 44.08% from -$1.41M to -$2.04M.
D
Sell
5/21/2014Downgrade
Diamedica Inc. (DMCAF) was downgraded to D- from D on 5/21/2014 due to a decline in the efficiency index and volatility index.
Diamedica Inc. (DMCAF) was downgraded to D- from D on 5/21/2014 due to a decline in the efficiency index and volatility index.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
